Anti‐LSSDS pharmacological components identification of YuHuangLian based on the combination of spectrum–effect analysis and network pharmacology as well as molecular docking
Biomedical Chromatography · 2024-12 · 38 (12)
DOI: 10.1002/bmc.5973 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, online erschienen am 24.09.2024. Verfasst von Beilei Xu und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Harbin University of Commerce, Harbin, China. Hauptthemen laut MEDLINE: Molecular Docking Simulation, Drugs, Chinese Herbal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Harbin Applied Technology Research and Exploitation Project, Nursing Program for Young Scholars with Creative Talents in Heilongjiang Province, Harbin University of Commerce Youth Academic Backbone Support Program.
Abstract (Originalsprache)
This research aimed to investigate the pharmacological components for liver stagnation and spleen deficiency syndrome (LSSDS) of Evodia rutaecarpa (also called Yu HuangLian [YHL]) by exploring the spectrum–effect relationship between fingerprints and pharmacological actions. The fingerprints of 17 batches of YHL with different preparation conditions according to Box–Behnken Design were generated and analyzed to identify the common peaks by HPLC and FT‐IR. Vasoactive intestinal peptide ( vip ), substance P, and 5‐HT levels in colon sample were measured by ELISA. Gray degree correlation and orthogonal partial least squares were employed to explore the correlation degree between components and pharmacologic activity. The presumed pharmacological components were further confirmed by network pharmacology, molecular docking, and qRT‐PCR. The columbamine, jatrorrhizine, coptisine, berberine, rutecarpine, and evodiamine of the 14 common peaks in HPLC fingerprints were significantly correlated with the pharmacological indexes. Similarly, there was a strong correlation with ‐OH, δ NC‐H, and ν C‐O‐C of the 10 common peaks in FT‐IR fingerprints. PTGS2 and CHRM3 were the main targets intervening LSSDS, and the presumed pharmacological components could markedly increase the expression of CHRM3 and obviously reduce the expression of PTGS2 compared with the model group.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Harbin University of Commerce, Harbin, China.
- Engineering Research Center of Natural Anti-cancer Drugs, Ministry of Education, Harbin, China.
- Heilongjiang Key Laboratory of Preventive and Therapeutic Drug Research of Senile Diseases, Harbin, China.
- Engineering Research Center of Chinese Medicine Production and New Drug Development, Beijing University of TCM, Beijing, China.
- National Institutes for Food and Drug Control, Beijing, China.
Förderung
- Harbin Applied Technology Research and Exploitation Project
- Nursing Program for Young Scholars with Creative Talents in Heilongjiang Province
- Harbin University of Commerce Youth Academic Backbone Support Program
- Heilongjiang Province Natural Science Foundation Joint Guidance Program
- Graduate Students Innovative Scientific Research Project of Harbin University of Commerce
- Discipline Construction of Institute of Chinese Medicine-Molecular Biology Identification of Chinese Patent Medicine Project
Zitieren
APA
Xu, B., Chen, S., Liu, J., Wu, D., Sun, W., Liu, S., Hu, Y., Wang, H., Wang, J., Yang, B., Li, W., & Ma, S. (2024). Anti‐LSSDS pharmacological components identification of YuHuangLian based on the combination of spectrum–effect analysis and network pharmacology as well as molecular docking. Biomedical Chromatography, 38(12). https://doi.org/10.1002/bmc.5973
Vancouver
Xu B, Chen S, Liu J, Wu D, Sun W, Liu S, et al. Anti‐LSSDS pharmacological components identification of YuHuangLian based on the combination of spectrum–effect analysis and network pharmacology as well as molecular docking. Biomedical Chromatography. 2024;38(12). doi:10.1002/bmc.5973
BibTeX
@article{Xu2024,
author = {Xu, Beilei and Chen, Shengnan and Liu, Jingjing and Wu, Di and Sun, Wenbin and Liu, Shusen and Hu, Yang and Wang, Hao and Wang, Jinhong and Yang, Bo and Li, Wenlan and Ma, Shuangcheng},
title = {Anti‐LSSDS pharmacological components identification of YuHuangLian based on the combination of spectrum–effect analysis and network pharmacology as well as molecular docking},
journal = {Biomedical Chromatography},
year = {2024},
volume = {38},
number = {12},
doi = {10.1002/bmc.5973}
}
EUVIMED